Cybin Inc. (NASDAQ:HELP – Get Free Report) saw some unusual options trading activity on Monday. Stock traders bought 3,723 call options on the stock. This is an increase of approximately 108% compared to the typical daily volume of 1,786 call options.
Analysts Set New Price Targets
Several brokerages recently weighed in on HELP. Wells Fargo & Company increased their target price on Cybin from $16.00 to $22.00 and gave the company an “overweight” rating in a report on Thursday, October 22nd. Barclays started coverage on Cybin in a research report on Friday, September 18th. They issued an “overweight” rating and a $35.00 price objective for the company. TD Cowen increased their price objective on Cybin from $8.00 to $62.00 and gave the company a “buy” rating in a research note on Thursday, August 20th. Finally, Wall Street Zen cut shares of Cybin from a “sell” rating to a “strong sell” rating in a report on Saturday, November 7th. Six analysts have rated the stock with a Buy rating. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $47.33.
View Our Latest Report on Cybin
Insider Buying and Selling at Cybin
In other Cybin news, CFO Greg Cavers purchased 3,000 shares of the stock in a transaction on Tuesday, September 29th. The stock was acquired at an average cost of $12.91 per share, with a total value of $38,730.00. Following the completion of the purchase, the chief financial officer directly owned 3,000 shares of the company’s stock, valued at approximately $38,730. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Eric H. L. So purchased 100,000 shares of the business’s stock in a transaction on Tuesday, September 8th. The shares were acquired at an average price of $12.39 per share, with a total value of $1,239,000.00. Following the completion of the transaction, the insider owned 4,465,014 shares of the company’s stock, valued at approximately $55,321,523.46. This trade represents a 2.29% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders purchased a total of 688,000 shares of company stock worth $8,422,830 in the last quarter. 15.00% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently made changes to their positions in the company. Royce & Associates LP purchased a new position in shares of Cybin in the third quarter worth $5,286,000. Blue Owl Capital Holdings LP boosted its position in shares of Cybin by 381.2% during the third quarter. Blue Owl Capital Holdings LP now owns 288,282 shares of the company’s stock valued at $3,543,000 after buying an additional 228,371 shares during the last quarter. Pale Fire Capital SE purchased a new stake in shares of Cybin during the second quarter valued at $1,015,000. ACT Capital Partners L.P. bought a new stake in Cybin in the 3rd quarter worth about $1,659,000. Finally, WealthPlan Investment Management LLC bought a new stake in Cybin in the 3rd quarter worth about $1,272,000. Hedge funds and other institutional investors own 17.94% of the company’s stock.
Cybin Trading Down 11.2%
NASDAQ HELP traded down $0.99 on Monday, hitting $7.88. The company’s stock had a trading volume of 10,994,020 shares, compared to its average volume of 1,327,331. The firm has a market cap of $628.82 million, a P/E ratio of -2.64 and a beta of 0.64. Cybin has a 52-week low of $3.76 and a 52-week high of $15.15. The company’s 50-day simple moving average is $11.24 and its 200 day simple moving average is $7.81.
Cybin (NASDAQ:HELP – Get Free Report) last posted its earnings results on Friday, November 13th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.74). On average, research analysts forecast that Cybin will post -2.95 EPS for the current fiscal year.
About Cybin
Cybin, which changed its name to Helus Pharma, is a clinical-stage biopharmaceutical company developing psychedelic-based treatments for mental health conditions. Its research focuses on designing and evaluating investigational compounds intended to address conditions including depression and anxiety disorders. The company’s pipeline has included CYB003, a deuterated psilocin analog being studied for major depressive disorder, and CYB004, an investigational DMT-based treatment studied for generalized anxiety disorder.
Read More
- Five stocks we like better than Cybin
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
- Embraer’s Record Backlog Looks Promising, But Can It Keep Its Margins Climbing?
Receive News & Ratings for Cybin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cybin and related companies with MarketBeat.com's FREE daily email newsletter.
